1-3 of 3
Anthony Boral, MD, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Herpes Zoster (HZ) Complicating Bortezomib Therapy of Relapsed/Refractory Indolent B-Cell and Mantle Cell Lymphoma: An Analysis of Two Phase II Trials.

Vicki A. Morrison, MD, Richard I Fisher, MD, Andre Goy, MD, Sven de Vos, Steven H. Bernstein, Anthony Boral, MD, PhD, Rachel Neuwirth, MS
Journal: Blood
Blood (2010) 116 (21): 2818.
https://doi.org/10.1182/blood.V116.21.2818.2818
Published: 2010
Journal Articles

Phase 2 Study of Bortezomib Weekly or Twice Weekly Plus Rituximab in Patients with Follicular (FL) or Marginal Zone (MZL) Lymphoma: Final Results.

Sven De Vos, MD, PhD, Shaker R. Dakhil, MD, FACP, Peter McLaughlin, Mansoor N. Saleh, MD, Robert Belt, MD, Christopher Flowers, MD, Charles Holladay, MD, Mark Knapp, MD, Anthony Boral, MD, PhD, Tracy Zhang, MS, Andre Goy, MD
Journal: Blood
Blood (2006) 108 (11): 694.
https://doi.org/10.1182/blood.V108.11.694.694
Published: 2006
Journal Articles

Phase II Clinical Study of Bortezomib (VELCADE®) in Patients (pts) with Relapsed / Refractory Non-Hodgkin’s Lymphoma (NHL) and Hodgkin’s Disease (HD).

Sandra J. Strauss, MD, Lenushka Maharaj, MSc, Jim Stec, Anthony Boral, MD, PhD, Elizabeth Trehu, MD, David Schenkein, MD, Simon P. Joel, PhD, T. Andrew Lister, MD
Journal: Blood
Blood (2004) 104 (11): 1386.
https://doi.org/10.1182/blood.V104.11.1386.1386
Published: 2004